A database of FDA approved therapeutic peptides and proteins
ID1032 | ThPPIDTh1006 | NameBivalirudin | Peptide SequenceFPRPGGGGNGDFEEIPEEYL Full view | Length20 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAngiomax | CompanyMedicines Co or MDCO | Physical AppearanceWhite lyophilized cake in single-use vials | Route of AdministartionIntravenous infusion | CategoryAntithrombins | TargetProthrombin |
ID1033 | ThPPIDTh1006 | NameBivalirudin | Peptide SequenceFPRPGGGGNGDFEEIPEEYL Full view | Length20 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAngiox | CompanyThe Medicines Company UK Ltd | Physical AppearancePowder for concentrate for solution | Route of AdministartionInjection | CategoryAntithrombins | TargetProthrombin |
ID1038 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEligard | CompanyAtrix Labs/QLT In | Physical AppearanceSuspension | Route of AdministartionSubcutaneous Injection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1039 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEnantone | CompanyTakeda | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1040 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeuplin | CompanyTakeda | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1041 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeuProMaxx | CompanyBaxter/Teva | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1042 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeupromer | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1043 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLupron | CompanyAbbott/TAP Pharmaceuticals | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1044 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLutrate | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1045 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandMemryte | CompanyCuraxis | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1046 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandProstap 3 | CompanyTakeda UK Limited | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1047 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandProstap SR | CompanyTakeda UK Limited | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1048 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandViadur | CompanyBayer AG | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1129 | ThPPIDTh1018 | NameSecretin | Peptide SequenceHSDGTFTSELSRLRDSARLQ Full view | Length27 | Functional ClassificationIV | DiseaseHormonal disorders | BrandSecreFlo | CompanyRepligen Corp | Physical AppearanceLyophilized white powder | Route of AdministartionIntravenous infusion | CategoryDiagnostic Agents | TargetSecretin receptor |
ID1130 | ThPPIDTh1018 | NameSecretin | Peptide SequenceHSDGTFTSELSRLRDSARLQ Full view | Length27 | Functional ClassificationIV | DiseaseHormonal disorders | BrandSecremax | CompanyRepligen Corp | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryDiagnostic Agents | TargetSecretin receptor |
ID1187 | ThPPIDTh1024 | NameGramicidin D | Peptide SequenceVGALAVVVWLWLWLWX Full view | Length16 | Functional ClassificationIIa | DiseaseInfectious | BrandNeosporin | CompanyPfizer | Physical AppearanceOintment | Route of AdministartionExternal use only | CategoryAnti-Bacterial Agents, Anti-infective, Topical, Antibiotic | TargetN.A. |
ID1188 | ThPPIDTh1024 | NameGramicidin D | Peptide SequenceVGALAVVVWLWLWLWX Full view | Length16 | Functional ClassificationIIa | DiseaseInfectious | BrandSofradex | CompanySanofi | Physical AppearanceSterile, clear, bright, colourless, aqueous solution | Route of AdministartionAuricular and Ocular use. | CategoryAnti-Bacterial Agents, Anti-infective, Topical, Antibiotic | TargetN.A. |
ID1252 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucaGen | CompanyNovo Nordisk | Physical AppearanceSterile, lyophilized white powder | Route of AdministartionSubcutaneous, Intramuscular, or Intravenous infusion | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1253 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucagon | CompanyEli Lilly | Physical AppearancePowder | Route of AdministartionSubcutaneously or Intramuscularly Injection | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1363 | ThPPIDTh1052 | NameEptifibatide | Peptide SequenceMpr-Har-Gly-Asp-Trp- Full view | Length7 | Functional ClassificationIb | DiseaseHematological/Metabolic | BrandINTEGRILIN | CompanySchering-Plough/Essex | Physical AppearanceClear, colorless, sterile, non-pyrogenic solution of Eptifibatide | Route of AdministartionInjection Solution for IIntravenousUse | CategoryPlatelet Aggregation Inhibitors | TargetLutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
ID1375 | ThPPIDTh1056 | NameVasopressin | Peptide SequenceCYFQNCPRG Full view | Length9 | Functional ClassificationIb | DiseaseHormonal | BrandPitressin | CompanyJHP Pharmaceuticals | Physical AppearanceSterile, aqueous solution of synthetic vasopressin | Route of AdministartionIntramuscular or Subcutaneous use | CategoryAntidiuretic Agents | TargetVasopressin V2 receptor,Vasopressin V1a receptor,Vasopressin V1b receptor |
ID1460 | ThPPIDTh1087 | NameOxytocin | Peptide SequenceCYIQNCPLG Full view | Length9 | Functional ClassificationIb | DiseaseHormonal | BrandPitocin | CompanyJHP Pharmaceuticals | Physical AppearanceSterile, clear, colorless aqueous solution of synthetic oxytocin | Route of AdministartionIntravenous infusion | CategoryOxytocics, Anti-tocolytic Agents and Labor Induction Agents | TargetInterferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Globotriaosylceramide |
ID1500 | ThPPIDTh1103 | NameCosyntropin | Peptide SequenceACTH(1-24): SYSM Full view | Length24 | Functional ClassificationIV | DiseaseHormonal | BrandCortrosyn | CompanyAmphastar Pharmaceuticals | Physical AppearanceN.A. | Route of AdministartionIntravenous injection, Intravenous infusion, Intramuscular injection | CategoryHormones and Diagnostic Agents | TargetAdrenocorticotropic hormone receptor |
ID1531 | ThPPIDTh1110 | NameThymalfasin | Peptide SequenceSDAAVDTSSEITTKDLKEKK Full view | Length28 | Functional ClassificationIb | DiseaseInfectious/Immunological | BrandZadaxin | CompanySciClone Pharmaceuticals (SCLN) | Physical AppearanceN.A. | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetN.A. |
ID1601 | ThPPIDTh1127 | NameBuserelin | Peptide SequencepGlu-His-Trp-Ser-Tyr Full view | Length9 | Functional ClassificationIIIc | DiseaseCancer/Hormonal | BrandSuprecur (injection) | CompanySanofi-Aventis | Physical Appearance1mg/ml Injection | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetLutropin-choriogonadotropic hormone receptor,Gonadotropin-releasing hormone receptor |
ID1641 | ThPPIDTh1146 | NameLucinactant | Peptide SequenceKLLLLKLLLLKLLLLKLLLL Full view | Length21 | Functional ClassificationIb | DiseaseGenetic | BrandSurfaxin | CompanyDiscovery Laboratories, Inc. | Physical AppearanceSuspension | Route of AdministartionIntratracheal administration | CategoryPulmonary surfactants | TargetN.A. |
ID1666 | ThPPIDTh1157 | NameSermorelin | Peptide SequenceYADAIFTNSYRKVLGQLSAR Full view | Length30 | Functional ClassificationIa | DiseaseHormonal | BrandSermorelin acetate | CompanyEmd serono inc | Physical AppearanceSterile, non-pyrogenic, lyophilized powder | Route of AdministartionSubcutaneous Injection | CategoryHormone Replacement Agents | TargetGrowth hormone-releasing hormone receptor |